Real-world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study

Journal of Viral Hepatitis

Volumn 24, Issue 1, 2017, Pages 22-27

  Tapper, E B ^a   Bacon, B R ^b   Curry, M P ^a   Dieterich, D T ^c   Flamm, S L ^d   Guest, L E ^e   Kowdley, K V ^f   Lee, Y ^e   Tsai, N C ^g   Younossi, Z M ^h   Afdhal, N H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Trio Health Analytics   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g QUEEN S MEDICAL CENTER   (United States)

^h INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

cirrhosis; ledipasvir; liver disease; ribavirin; sofosbuvir

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; UNIVERSITY HOSPITAL; ANALOGS AND DERIVATIVES; CLASSIFICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 85006977310     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12611     Document Type: Article

References (22)

1. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
2. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
3. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–659.
4. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100–107 e1.
5. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485–1494.
6. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1,-2, and-3 clinical trials. Hepatology. 2015;61:1798–1808.
7. Hoofnagle JH, Sherker AH. Therapy for hepatitis C—the costs of success. N Engl J Med. 2014;370:1552–1553.
8. Liang TJ, Ghany MG. Therapy of hepatitis C—back to the future. N Engl J Med. 2014;370:2043–2047.
9. Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol. 2014;12:1371–1380.
10. Sethi N, Tapper E, Vong A, Sethi S, Rourke M, Afdhal N. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. J Viral Hepatitis. 2015;22:974–976.
11. Kanwal F, El-Serag HB. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. Clin Gastroenterol Hepatol. 2014;12:1381–1383.
12. Backus L, Belperio P, Shahoumian T, Loomis T, Mole L. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans. Aliment Pharmacol Ther. 2015;42:559–573.
13. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Inter. 2015;36:651–658.
14. Pillai AA, Wedd J, Norvell J, et al. Simeprevir and sofosbuvir (SMV–SOF) for 12 weeks for the treatment of chronic hepatitis C genotype 1 infection: a real world (Transplant) hepatology practice experience. Am J Gastroenterol. 2016;111:250–260.
15. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naïve genotype 1 hepatitis C infected patients. Hepatology. 2016;64:405–414.
16. Aghemo A, Donato MF. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology. 2015;148:13.
17. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397–406.
18. Pho M, Jensen D, Meltzer D, Kim A, Linas B. Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepatitis. 2015;22:630–638.
19. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2015;150:419–429.
20. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
21. Bonder A, Tapper EB, Afdhal NH. Contemporary assessment of hepatic fibrosis. Clin Liver Dis. 2015;19:123–134.
22. Tapper EB, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol. 2015;13:27–36.